Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study | Synapse
September 16, 2025
Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study
Key Points
T-cell densities at baseline effectively distinguish responders from non-responders in urothelial cancer.
In ipilimumab-high cohorts, responders showed significantly higher T-cell densities than non-responders.
The analysis focused on T-cell subsets in cohorts receiving ipilimumab-high versus ipilimumab-low treatments.
Findings support the potential for T-cell subset analysis in predicting treatment responses in urothelial cancer.
Abstract
T-cell subsets at baseline between responders and non-responders for ipilimumab-high and ipilimumab-low. a. T-cell densities at baseline for responders (blue;